We recently emailed you to update you on the Managed Access Agreement for Translarna. We know that some of you had questions about this. To try and answer your questions we have worked with Muscular Dystrophy UK to create a Question and Answer document about Translarna and the Managed Access Agreement.
View the frequently asked questions
If you would like any more information about Translarna or the MAA process, please contact Neil Bennett(Action Duchenne) or Clare Lucas (MDUK).
We will continue to campaign to make sure that emerging treatments for Duchenne get to people as quickly as possible.
ReveraGen receives FDA fast track designation for Vamorolone
